Immix Biopharma Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
9.3%projected annual EPS growth
Analyst Coverage
8analysts covering
FY EPS (est.)
-$0.71next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| NEXICART-2 1-Year Follow-Up Data Presentation | 31 Mar 2027 |
Monitoring Framework
Key Performance Indicators
NEXICART-2 Complete Response (CR) Rate Quarterly95.0%Target: 75 or higher%
NEXICART-2 Patient Enrollment Count Quarterly45Target: 45 (Fully Enrolled)
Cash and Short-Term Investments Quarterly90.6MTarget: Sufficient to fund operations for at least 12 months
Watch Items
- Topline NEXICART-2 Clinical Trial ResultsTrigger: Q3 2026Action: Evaluate efficacy (CR rate, MRD-negativity) and safety profile to support BLA filing.
- Biologics License Application (BLA) Submission for NXC-201Trigger: Post-1-year follow-up data (expected by end of March 2027)Action: Prepare regulatory dossier and coordinate with FDA under Breakthrough Therapy and RMAT designations.
- Initiation of Phase 3 Trial in Newly Diagnosed AL AmyloidosisTrigger: Following NEXICART-2 topline resultsAction: Finalize protocol design for a multi-center, randomized Phase 3 trial to expand NXC-201 into frontline therapy.
Research as of 19 Jun 2026